Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Background The duration of protection against the omicron (B.1.1.529) variant for current COVID-19 vaccines is not well characterised. Vaccine-specific estimates are especially needed. We aimed to evaluate the effectiveness and durability of two and three doses of the BNT162b2 (Pfizer–BioNTech) mRNA vaccine against hospital and emergency department admissions due to the delta (B.1.617.2) and omicron variants. Methods In this case–control study with a test-negative design, we analysed electronic health records of members of Kaiser Permanente Southern California (KPSC), a large integrated health system in California, USA, from Dec 1, 2021, to Feb 6, 2022. Vaccine effectiveness was calculated in KPSC patients aged 18 years and older admitted to hospital or an emergency department (without a subsequent hospital admission) with a diagnosis of acute respiratory infection and tested for SARS-CoV-2 via PCR. Adjusted vaccine effectiveness was estimated with odds ratios from adjusted logistic regression models. This study is registered with ClinicalTrials.gov (NCT04848584). Findings Analyses were done for 11 123 hospital or emergency department admissions. In adjusted analyses, effectiveness of two doses of the BNT162b2 vaccine against the omicron variant was 41% (95% CI 21–55) against hospital admission and 31% (16–43) against emergency department admission at 9 months or longer after the second dose. After three doses, effectiveness of BNT162b2 against hospital admission due to the omicron variant was 85% (95% CI 80–89) at less than 3 months but fell to 55% (28–71) at 3 months or longer, although confidence intervals were wide for the latter estimate. Against emergency department admission, the effectiveness of three doses of BNT162b2 against the omicron variant was 77% (72–81) at less than 3 months but fell to 53% (36–66) at 3 months or longer. Trends in waning against SARS-CoV-2 outcomes due to the delta variant were generally similar, but with higher effectiveness estimates at each timepoint than those seen for the omicron variant. Interpretation Three doses of BNT162b2 conferred high protection against hospital and emergency department admission due to both the delta and omicron variants in the first 3 months after vaccination. However, 3 months after receipt of a third dose, waning was apparent against SARS-CoV-2 outcomes due to the omicron variant, including hospital admission. Additional doses of current, adapted, or novel COVD-19 vaccines might be needed to maintain high levels of protection against subsequent waves of SARS-CoV-2 caused by the omicron variant or future variants with similar escape potential. Funding Pfizer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern
Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O’Connell, A.-M., et al. (2021) · doi:10.1101/2021.12.14.21267615 · Cited by 2,420
Cele, S., Jackson, L., Khoury, D. S., Khan, K., Moyo-Gwete, T., Tegally, H., San, J. E., Cromer, D., Scheepers, C., Amoako, D., et al. (2021) · doi:10.1101/2021.12.08.21267417 · Cited by 1,333
Tartof, S. Y., Slezak, J. M., Fischer, H., Hong, V., Ackerson, B. K., Ranasinghe, O. N., Frankland, T. B., Ogun, O. A., Zamparo, J. M., Gray, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02183-8 · Cited by 1,167
Self-citationWolter, N., Jassat, W., Walaza, S., Welch, R., Moultrie, H., Groome, M., Amoako, D. G., Everatt, J., Bhiman, J. N., Scheepers, C., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00017-4 · Cited by 1,041
Tarke, A., Coelho, C. H., Zhang, Z., Dan, J. M., Yu, E. D., Methot, N., Bloom, N. I., Goodwin, B., Phillips, E., Mallal, S., et al. (2022) · Cell · doi:10.1016/j.cell.2022.01.015 · Cited by 858
Accorsi, E. K., Britton, A., Fleming-Dutra, K. E., Smith, Z. R., Shang, N., Derado, G., Miller, J., Schrag, S. J., & Verani, J. R. (2022) · JAMA · doi:10.1001/jama.2022.0470 · Cited by 628
Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
Collie, S., Champion, J., Moultrie, H., Bekker, L.-G., & Gray, G. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119270 · Cited by 600
Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants
Tseng, H. F., Ackerson, B. K., Luo, Y., Sy, L. S., Talarico, C. A., Tian, Y., Bruxvoort, K. J., Tubert, J. E., Florea, A., Ku, J. H., et al. (2022) · doi:10.1101/2022.01.07.22268919 · Cited by 541
Self-citationThe test-negative design for estimating influenza vaccine effectiveness
Jackson, M. L., & Nelson, J. C. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.02.053 · Cited by 510
Research works printed but not linked: 28
- Viana, 2022, Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa, Nature, 603, 679, 10.1038/s41586-022-04411-y · DOI · Paper page
- Cele, 2022, Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization, Nature, 602, 654, 10.1038/s41586-021-04387-1 · doi:10.1038/s41586-021-04387-1 · Paper page
- Nemet, 2022, Third BNT162b2 vaccination neutralization of SARS-CoV-2 omicron infection, N Engl J Med, 386, 492, 10.1056/NEJMc2119358 · DOI · Paper page
- De Marco, 2021, Preserved T cell reactivity to the SARS-CoV-2 Omicron variant indicates continued protection in vaccinated individuals, bioRxiv
- GeurtsvanKessel, 2022, Divergent SARS-CoV-2 omicron-reactive T and B cell responses in COVID-19 vaccine recipients, Sci Immunol, 7, 10.1126/sciimmunol.abo2202 · DOI · Paper page
- Liu, 2022, Vaccines elicit highly cross-reactive cellular immunity to the SARS-CoV-2 omicron variant, medRxiv
- Keeton, 2022, T cell responses to SARS-CoV-2 spike cross-recognize Omicron, Nature, 603, 488, 10.1038/s41586-022-04460-3 · DOI · Paper page
- Danza, 2022, SARS-CoV-2 infection and hospitalization among adults aged ≥18 years, by vaccination status, before and during SARS-CoV-2 B.1.1.529 (omicron) variant predominance — Los Angeles County, California, November 7, 2021–January 8, 2022, MMWR Morb Mortal Wkly Rep, 71, 177, 10.15585/mmwr.mm7105e1 · DOI
- Buchan, 2022, Effectiveness of COVID-19 vaccines against Omicron or Delta infection, medRxiv
- Chemaitelly, 2022, Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 Omicron infection in Qatar, medRxiv
- Andrews, 2022, Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant, N Engl J Med, 10.1056/NEJMoa2119451 · doi:10.1056/nejmoa2119451 · Paper page
- Koebnick, 2012, Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data, Perm J, 16, 37, 10.7812/TPP/12-031 · DOI · Paper page
- Scott, 2021, Track Omicron's spread with molecular data, Science, 374, 1454, 10.1126/science.abn4543 · DOI · Paper page
- Turner, 2021, SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses, Nature, 596, 109, 10.1038/s41586-021-03738-2 · DOI · Paper page
- Arunachalam, 2021, Systems vaccinology of the BNT162b2 mRNA vaccine in humans, Nature, 596, 410, 10.1038/s41586-021-03791-x · DOI · Paper page
- Teijaro, 2021, COVID-19 vaccines: modes of immune activation and future challenges, Nat Rev Immunol, 21, 195, 10.1038/s41577-021-00526-x · DOI · Paper page
- Bruxvoort, 2021, Recombinant adjuvanted zoster vaccine and reduced risk of COVID-19 diagnosis and hospitalization in older adults, J Infect Dis
- Pozzetto, 2021, Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination, Nature, 600, 701, 10.1038/s41586-021-04120-y · DOI · Paper page
- Parry, 2021, Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people, Immun Ageing, 18, 34, 10.1186/s12979-021-00246-9 · DOI
- Liu, 2021, Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial, Lancet, 398, 856, 10.1016/S0140-6736(21)01694-9 · DOI · Paper page
- Munro, 2021, Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial, Lancet, 398, 2258, 10.1016/S0140-6736(21)02717-3 · DOI · Paper page
- Atmar, 2022, Homologous and heterologous Covid-19 booster vaccinations, N Engl J Med, 386, 1046, 10.1056/NEJMoa2116414 · DOI · Paper page
- GeurtsvanKessel, 2022, Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients, Sci Immunol, 10.1126/sciimmunol.abo2202 · DOI · Paper page
- Bar-On, 2022, Protection by 4th dose of BNT162b2 against Omicron in Israel, medRxiv
- De Serres, 2013, The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials, Euro Surveill, 18, 10.2807/1560-7917.ES2013.18.37.20585 · DOI · Paper page
- Haber, 2015, A probability model for evaluating the bias and precision of influenza vaccine effectiveness estimates from case-control studies, Epidemiol Infect, 143, 1417, 10.1017/S0950268814002179 · DOI
- Lipsitch, 2016, Observational studies and the difficult quest for causality: lessons from vaccine effectiveness and impact studies, Int J Epidemiol, 45, 2060
- Iuliano, 2022, Trends in disease severity and health care utilization during the early omicron variant period compared with previous SARS-CoV-2 high transmission periods - United States, December 2020-January 2022, MMWR Morb Mortal Wkly Rep, 71, 146, 10.15585/mmwr.mm7104e4 · DOI · Paper page
Cited by
Lewnard, J. A., Hong, V. X., Patel, M. M., Kahn, R., Lipsitch, M., & Tartof, S. Y. (2022) · Nature Medicine · doi:10.1038/s41591-022-01887-z · Cited by 390
Self-citationStowe, J., Andrews, N., Kirsebom, F., Ramsay, M., & Bernal, J. L. (2022) · Nature Communications · doi:10.1038/s41467-022-33378-7 · Cited by 166
Neutralising antibodies predict protection from severe COVID-19
Cromer, D., Steain, M., Reynaldi, A., Schlub, T. E., Sasson, S. C., Kent, S. J., Khoury, D. S., & Davenport, M. P. (2022) · doi:10.1101/2022.06.09.22275942 · Cited by 139
Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years
Winokur, P., Gayed, J., Fitz-Patrick, D., Thomas, S. J., Diya, O., Lockhart, S., Xu, X., Zhang, Y., Bangad, V., Schwartz, H. I., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2213082 · Cited by 116
Tseng, H. F., Ackerson, B. K., Bruxvoort, K. J., Sy, L. S., Tubert, J. E., Lee, G. S., Ku, J. H., Florea, A., Luo, Y., Qiu, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35815-7 · Cited by 105
Self-citation
Metadata
- Authors
- Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V., Xie, F., Ackerson, B. K., Valluri, S. R., Jodar, L., & McLaughlin, J. M.
- Venue
- The Lancet Respiratory Medicine
- Publisher
- Elsevier BV
- Published
- 2022-07
- Volume
- 10
- Issue
- 7
- Pages
- 689-699
- ISSN
- 2213-2600 (ISSN-L)
- OpenAlex
- W4224233017
- Cited by
- 140
- References
- 17
- FWCI
- 14.97
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Funders
- Pfizer Inc Boulder
- Pfizer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study. https://app.cochat.ai/papers/10.1016/s2213-2600(22)00101-1
- The paper
- Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V., Xie, F., Ackerson, B. K., Valluri, S. R., Jodar, L., & McLaughlin, J. M. (2022). Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(22)00101-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.